Check out the TB2K CHATROOM, open 24/7               Configuring Your Preferences for OPTIMAL Viewing
  To access our Email server, CLICK HERE

  If you are unfamiliar with the Guidelines for Posting on TB2K please read them.      ** LINKS PAGE **



*** Help Support TB2K ***
via mail, at TB2K Fund, P.O. Box 24, Coupland, TX, 78615
or


HEALTH FDA OKs 1st drug to treat smallpox, in case of terror attack
+ Reply to Thread
Results 1 to 7 of 7
  1. #1
    Join Date
    Jan 2012
    Location
    OK
    Posts
    28,292

    FDA OKs 1st drug to treat smallpox, in case of terror attack

    U.S. regulators have approved the first treatment for smallpox — a deadly disease that was wiped out four decades ago — in case the virus is used in a terror attack.

    Smallpox, which is highly contagious, was eradicated worldwide by 1980 after a huge vaccination campaign.

    But people born since then haven’t been vaccinated, and small samples were saved for research purposes, leaving the possibility it could be used as a biological weapon.

    The U.S. Food and Drug Administration approved the drug, called TPOXX (TEE’-pochs), on Friday. The maker, SIGA Technologies of New York, has already delivered 2 million treatments for stockpiling by the government.

    To test the treatment, animals were infected with a similar virus and then given the drug. Ninety percent survived.

    https://www.breitbart.com/news/fda-o...terror-attack/
    Proud Infidel...............and Cracker

    Member: Nowski Brigade

    Deplorable


  2. #2
    Join Date
    Sep 2016
    Location
    West Central Alabama
    Posts
    65
    Animals were given a "similar virus" ? Just wondering what happened to the human trials that's sometimes required for a new drug and how effective it will be against the actual small pox virus.

  3. #3
    Join Date
    May 2001
    Location
    Behind Enemy Lines
    Posts
    154,446
    Hell, I’m just trying to get my second shingle vax...

  4. #4
    Join Date
    Oct 2002
    Location
    Back in Iowa, where I belong
    Posts
    2,589
    I seem to recall reading right here on this forum that Cream of Tartar will cure smallpox, because someone found a claim by a physician from around 1910 or so saying so.

    Quite the thread on smallpox here back in the day.

    RR
    Survival and Austere Medicine: An Introduction - 2nd and 3rd Editions Contributing author and editor

    Get your FREE copy of the 3rd edition here:NNPG Download Site

    Reddit AustereMedicine/

  5. #5
    Join Date
    Mar 2009
    Location
    A Socialist State
    Posts
    20,080
    I'm not taking ANY flipping vaccines from anyone!
    Don't just go to church. BE THE CHURCH!

  6. #6
    Join Date
    May 2001
    Location
    Behind Enemy Lines
    Posts
    154,446
    As an old guy, I don’t want pneumonia or shingles. I’ve had a marked propensity for bronchitis all my life, and it’s gone into pneumonia a couple times.

  7. #7
    The drug was tested on animals infected with monkeypox-it's similar to smallpox and can be weaponized just like smallpox.

    Here's a snip from drugs.com about early testing results on their new product.

    The idiots at the CDC got rid of the doses of Dryvax before this drug was approved. Idiots. And Dryvax was still a viable vaccine when they did it-it wasn't expired and CDC did testing to stretch the available supply to boot. Idiots.

    SIGA Completes 21 Day Multi-Dose Human Clinical Safety andDose-Ranging Trial of Its Lead Smallpox Drug ST-246
    Facebook Twitter Google Plus Email to a friend Print this page
    SIGA Completes 21 Day Multi-Dose Human Clinical Safety and Dose-Ranging Trial of Its Lead Smallpox Drug ST-246

    NEW YORK, Dec. 6, 2007 (PRIME NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its lead drug candidate, ST-246, has successfully completed another human clinical trial.

    Although the final study report is not yet available, preliminary results indicate that the drug is safe and well-tolerated at all tested doses when administered orally for 21 days to healthy human volunteers. In addition, blood level exposures were dose-dependent, and the levels obtained in the volunteers were the same as those previously shown to protect monkeys from disease and subsequent death in challenge models. Furthermore, the drug's half-life was sufficient to support once-a-day dosing. This data reinforces SIGA's ability to establish that ST-246 will be not only a potent therapeutic drug against smallpox, but a safe and reliable one as well.

    "We are very pleased with the results of this second safety study with ST-246. The data obtained here will be an important and helpful part of our full submission for FDA approval," said Dr. Eric A. Rose, Chief Executive Officer of SIGA.

    The clinical trial, considered a "Phase I" trial by the FDA, was performed at the Orlando Clinical Research Center in Orlando, Florida. The study was a double-blind, randomized, placebo-controlled, ascending multiple-dose study in healthy volunteers.

    SIGA believes that ST-246 is the most advanced smallpox treatment currently in development. ST-246 represents a new approach to achieve a novel, orally active, antiviral therapeutic. It has demonstrated significant antiviral activity in various animal models of poxvirus disease, including the complete protection of primates from lethal doses of monkeypox and smallpox virus. SIGA will use animal efficacy data as part of its full FDA approval submission under the FDA's "Animal Efficacy Rule." In December 2005, the FDA granted "fast-track" status to ST-246. In December 2006, the FDA granted to ST-246 an orphan drug designation.

    This project has been funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, in conjunction with the National Institute of Allergy and Infectious Disease, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600014C.

    In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).

    About SIGA Technologies, Inc.

    SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at www.siga.com.

    The SIGA Technologies, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4504

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts


NOTICE: Timebomb2000 is an Internet forum for discussion of world events and personal disaster preparation. Membership is by request only. The opinions posted do not necessarily represent those of TB2K Incorporated (the owner of this website), the staff or site host. Responsibility for the content of all posts rests solely with the Member making them. Neither TB2K Inc, the Staff nor the site host shall be liable for any content.

All original member content posted on this forum becomes the property of TB2K Inc. for archival and display purposes on the Timebomb2000 website venue. Said content may be removed or edited at staff discretion. The original authors retain all rights to their material outside of the Timebomb2000.com website venue. Publication of any original material from Timebomb2000.com on other websites or venues without permission from TB2K Inc. or the original author is expressly forbidden.



"Timebomb2000", "TB2K" and "Watching the World Tick Away" are Service Mark℠ TB2K, Inc. All Rights Reserved.